Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-versus-host disease (CROSBI ID 229629)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Čeović, Romana ; Desnica, Lana ; Pulanić, Dražen ; Serventi Seiwerth, Ranka ; Ilić, Ivana ; Grce, Magdalena ; Mravak Stipetić, Marinka ; Klepac Pulanić, Tajana ; Bilić, Ervina ; Bilić, Ernest et al. High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-versus-host disease // Croatian medical journal, 57 (2016), 3; 229-238. doi: 10.3325/cmj.2016.57.229

Podaci o odgovornosti

Čeović, Romana ; Desnica, Lana ; Pulanić, Dražen ; Serventi Seiwerth, Ranka ; Ilić, Ivana ; Grce, Magdalena ; Mravak Stipetić, Marinka ; Klepac Pulanić, Tajana ; Bilić, Ervina ; Bilić, Ernest ; Milošević, Milan ; Vrhovac, Radovan ; Nemet, Damir ; Pavletić, Steven Živko

engleski

High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-versus-host disease

Aim: To show the frequency and characteristics of cutaneous manifestations, with emphasis on vitiligo and alopecia areata in patients with chronic graft-versus-host disease (cGVHD). Methods: Patients with cGVHD were prospectively enrolled in the observational study protocol and evaluated by a multidisciplinary team of specialists. Dermatologic evaluation was focused on clinical spectrum of skin and adnexal involvement in each patient, determining the cutaneous GVHD score according to NIH Consensus criteria. Other objective clinical parameters including the existence of vitiligo, alopecia, xerosis, nail changes and dyspigmentation were assessed in each patient. Results: Among fifty cGVHD patients, 28 (56%) had skin involvement, and twenty seven of them (96%) had hypo and/or hyperpigmentations. In 11 patients (39%) the cutaneous NIH cGVHD score was mild, in 22% moderate and in 39% severe. In the whole cohort, nail changes were observed in 15 (30%) patients, while 10 (20%) were diagnosed with vitiligo or alopecia areata. In the univariate analysis patients with vitiligo/alopecia areata received more lines of prior systemic immunosuppressive therapy (P=0.043) ; they had lower Karnofsky performance status (P=0.028), and had higher number of B- cells (P=0.005), platelet count (P=0.022), total protein (P=0.024). Vitiligo and alopecia areata were associated with higher NIH skin score (P=0.001), were receiving higher intensity of immunosuppressive treatment (P=0.020) and TBI conditioning (P=0.040). In a multivariate regression model patients with higher NIH skin scoring were 3.67 times more likely to have alopecia and/or vitiligo (OR=3.67 ; 95% CI=1.26-10.73), controlled for all other factors in the model (age at study entry, number of B-cells, platelet count and global NIH score). Conclusion: These data indicate that vitiligo and alopecia areata occur more frequently in cGVHD than reported previously.

Cutaneous GVHD ; vitiligo ; alopecia areata ; xerosis

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

57 (3)

2016.

229-238

objavljeno

0353-9504

1332-8166

10.3325/cmj.2016.57.229

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost